Therefore, targeting IRAK1, which is a key component of TLR-mediated NLRP3 inflammasome activation, could be a promising therapeutic strategy to alleviate he chronic inflammation associated with SARS-CoV-2 and HIV-1 infections [71]. This evidence concerns the gene NLRP3 and HIV-1 infection.